Factors predicting survival in surgical palliative resection of stage IV colorectal cancer

被引:1
作者
Scabini, S. [1 ]
Rimini, E. [1 ]
Romairone, E. [1 ]
Scordamaglia, R. [1 ]
Pertile, D. [1 ]
Ferrando, V. [1 ]
机构
[1] AOUS Martino, Dept Oncol & Surg, Genoa, Italy
关键词
Colonic neoplasms; surgery; Rectal neoplasm; Carcinoembryonic antigen binding protein; human; LONG-TERM SURVIVAL; PROGNOSTIC VARIABLES; LIVER METASTASES; CARCINOMA; SURGERY; COLON; MANAGEMENT;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Aim. Colorectal cancer (CRC) harbors accumulated genetic alterations with cancer progression, which results in uncontrollable disease. To regulate the most malignant CRC, we have to know the most dismal phenotype of stage IV disease. Methods. A retrospective review of our Oncological Surgical Unit was performed (from 2005 to 2008) to extract the 52 resected stage IV CRC. Clinical variables were tested for their relationship to survival in a univariate prognostic analysis and revealed the interaction of the prognostic factors. Results. In stage IV CRC with noncurable resection, the most robust univariate predictors for poor prognosis were preoperative high value of CEA. In our series we did not observe correlation between poor prognosis and depth of invasion, age, gender, pathologic lymph node metastasis status, Ca 19.9 and postoperative therapy. The mean average survival rate was 10.9 months. Conclusion. Our results suggested that only preoperative value CEA is associated with poor prognosis in stage IV CRC.
引用
收藏
页码:303 / 306
页数:4
相关论文
共 33 条
[1]  
[Anonymous], GEN RUL CLIN PATH ST
[2]  
BOEY J, 1981, SURG GYNECOL OBSTET, V153, P864
[3]  
CHANEZ J F, 1989, Skin Pharmacology, V2, P15
[4]   Carcinoembryonic antigen and albumin predict survival in, patients with advanced colon and rectal cancer [J].
Dixon, MR ;
Haukoos, JS ;
Udani, SM ;
Naghi, JJ ;
Arnell, TD ;
Kumar, RR ;
Stamos, MJ .
ARCHIVES OF SURGERY, 2003, 138 (09) :962-966
[5]  
Fong Y, 1996, SEMIN SURG ONCOL, V12, P219, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.3.CO
[6]  
2-O
[7]  
Fountzilas G, 1996, MED PEDIATR ONCOL, V26, P305, DOI 10.1002/(SICI)1096-911X(199605)26:5<305::AID-MPO2>3.0.CO
[8]  
2-M
[9]  
Gorog D, 1997, Acta Chir Hung, V36, P106
[10]  
Hotta T, 2006, ANTICANCER RES, V26, P1377